RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Seems OddSf, I think it is safe to assume that future trials will be moving forward, thus the positive peer review articles, the one question that still remains is who is paying for this trial? Dart, partnership with bp or more damn dilutive financing, Or Vc. The longer this goes with less info the more I feel that discussions are on going with someone, who that I have no idea but I prefer bp,
as for zenith epigenetics, this is huge biotech field and I believe any pharma or big biotech that does have a stake in this field might be intertested in partnering or licensing with zenith, maybe the part will begin with a deal